Roche’s Announcement Regarding giredestrant (Presentation of Phase III evERA Study Results)

TOKYO, September 24, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on September 22, regarding giredestrant of topline results from a global Phase III clinical trial (evERA) in estrogen receptor (ER)- positive breast cancer.

The study met its co-primary endpoints, giredestrant in combination with everolimus demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the intention-to-treat and ESR1-mutated populations, compared with standard-of-care endocrine therapy plus everolimus. The giredestrant in combination with everolimus was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments, and no new safety signals were observed.

The detailed data will be presented at an upcoming medical meeting.

Please refer to the link below for details of the press release:

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

https://www.roche.com/media/releases/med-cor-2025-09-22

Trademarks used or mentioned in this release are protected by laws.